Biogen's (BIIB) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $311.00 target price on the biotechnology company’s stock. Several other research analysts have also recently issued reports on BIIB. Stifel Nicolaus dropped their price target […]